Abstract
Background Multi organ dysfunction syndrome caused by systemic inflammation after trauma is responsible for a high number of deaths worldwide. The cytokine Migration Inhibitory Factor (MIF) is recognized as a modulator of inflammatory response, however, its role in trauma is unknown. The aim of this study was to investigate (a) the levels of MIF in serum of trauma patients and of rats after hemorrhagic shock, (b) the potential of the MIF tautomerase activity inhibitor ISO-1 to reduce multi organ dysfunction syndrome in an acute and chronic hemorrhagic shock rat model and (c) whether treatment with ISO-1 attenuates NF-κB and NLRP3 activation in hemorrhagic shock.
Methods The serum MIF-levels in trauma patients and rats with hemorrhagic shock were measured by Enzyme-Linked Immunosorbent Assays. Acute and chronic hemorrhagic shock rat models were performed to determine the influence of ISO-1 on multi organ dysfunction syndrome. The activation of NF-κB and NLRP3 pathways were analyzed by western blot.
Results We demonstrated that (a) MIF levels are increased in serum of trauma patients on arrival in the emergency room and in serum of rats after hemorrhagic shock, (b) hemorrhagic shock caused organ damage and low blood pressure (after resuscitation) in rats, while (c) treatment of hemorrhagic shock rats with ISO-1 attenuated organ injury and dysfunction in acute and chronic hemorrhagic shock rat models and (d) decreased the activation of NF-κB and NLRP3 pathways.
Conclusion Our results point to a role of MIF in the pathophysiology of the organ injury and dysfunction caused by trauma/hemorrhage and indicate that MIF tautomerase activity inhibitors may have potential in the therapy of the multi organ dysfunction syndrome after trauma and/or hemorrhage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NMP was funded by the William Harvey Research Foundation, HPR and FRMBO were funded by National Council for Scientific and Technological Development (CNPq) fellowship. This study was supported by the German Research Foundation to LM (DFG, MA 7082/3-1), to CS (DFG, STO 1099/8-1) and by an intramural grant to EZ (START 131/19), National Council for Scientific and Technological Development to RS (CNPq, Brazil, Grant 409018/2018-0).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate Blood samples of 208 patients were collected after written informed consent was obtained from either patient or a nominated legally authorized representative as approved by the ethical committee. Samples of the included subjects were collected between years 2010-2014 from University Hospital Frankfurt of Goethe-University and approved by an institutional ethics committee (number 312/10) in accordance with the declaration of Helsinki and following STROBE-guidelines. Ethical approval was given to Department of Trauma, Hand and Reconstructive Surgery, University Hospital Frankfurt, Johann Wolfgang Goethe University, Theodor Stern Kai 7, Frankfurt D-60590, Germany. For the acute HS model, the Animal Welfare Ethics Review Board (AWERB) of Queen Mary University of London approved all experiments in accordance with the Home Office Guidance on the Operation of Animals (Scientific Procedure Act, 1986) published by Her Majesty's Stationary Office, and the Guide for the Care and Use of Laboratory Animals of the National Research Council. Work was conducted under UK Home Office Project License Number PC5F29685. Ethical approval was given to Professor Christoph Thiemermann, Department of Translational Medicine & Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, United Kingdom For the chronic HS model, all animal care and experimental procedures were approved by Universidade Federal de Santa Catarina Institutional Committee for Animal Use in Research (License number 7396250219) and are in accordance to the Brazilian Government Guidelines for Animal Use in Research (CONCEA). Ethical approval was given to Department of Pharmacology, Universidade Federal de Santa Catarina, SC, 88040-900, Brazil. All in vivo experiments are reported in accordance to ARRIVE guidelines. Consent for publication Informed consent was obtained from all subjects involved in the study or their legal representatives.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- ALT
- alanine aminotransferase
- AST
- aspartate aminotransferase
- CCr
- creatinine clearance
- CD
- Cluster of Differentiation
- CK
- creatine kinase
- DAMP
- damage-associated molecular patterns
- HR
- heart rate
- HS
- hemorrhagic shock
- ICU
- intensive care unit
- ISS
- Injury Severity Score
- LDH
- lactate dehydrogenase
- MAP
- mean arterial pressure
- MIF
- macrophage migratory inhibition factor
- MODS
- multi organ dysfunction syndrome
- MPO
- myeloperoxidase
